ALK and Grandpharma team up to market first adrenaline autoinjector in China

31 July 2021

Danish allergy immunotherapy specialist ALK Abello (ALKB: DC) has announced an exclusive licensing agreement with China Grand Pharmaceutical and Healthcare Holdings (Grandpharma), that will see ALK’s adrenaline auto-injector (AAI) Jext registered and launched in China, and will expand ALK's presence in the country.

Grandpharma is the leading supplier of adrenaline ampoules in China today and the company has extensive commercial reach within clinics and emergency care. Under the long-term agreement, Grandpharma will be responsible for the registration, import and commercialisation of ALK's AAI Jext in Mainland China, Macau and Taiwan, while ALK will be responsible for product supply and will offer marketing support based on its extensive experience in Europe and other markets.

Financial terms of the collaboration

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK